Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2025)

BioXcel Therapeutics has reported Change in Inventory over the past 4 years, most recently at $263000.0 for Q4 2025.

  • Quarterly results put Change in Inventory at $263000.0 for Q4 2025, up 131.09% from a year ago — trailing twelve months through Dec 2025 was $43000.0 (up 103.28% YoY), and the annual figure for FY2025 was $43000.0, up 103.28%.
  • Change in Inventory for Q4 2025 was $263000.0 at BioXcel Therapeutics, up from -$47000.0 in the prior quarter.
  • Over the last five years, Change in Inventory for BTAI hit a ceiling of $713000.0 in Q2 2022 and a floor of -$1.2 million in Q3 2024.
  • Median Change in Inventory over the past 4 years was -$7000.0 (2022), compared with a mean of $45125.0.
  • Peak annual rise in Change in Inventory hit 1457.58% in 2024, while the deepest fall reached 3033.33% in 2024.
  • BioXcel Therapeutics' Change in Inventory stood at $577000.0 in 2022, then crashed by 104.68% to -$27000.0 in 2023, then crashed by 3033.33% to -$846000.0 in 2024, then skyrocketed by 131.09% to $263000.0 in 2025.
  • The last three reported values for Change in Inventory were $263000.0 (Q4 2025), -$47000.0 (Q3 2025), and -$136000.0 (Q2 2025) per Business Quant data.